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The complexity of the tumor microenvironment necessitates that cell behavior is studied in a broad, multi-scale context.
Although tomographic and microscopy-based far and near infrared fluorescence (NIRF, .650 nm) imaging methods offer high
resolution, sensitivity, and depth penetration, there has been a lack of optimized NIRF agents to label and track cells in their
native environments at different scales. In this study we labeled mammalian leukocytes with VivoTag 680 (VT680), an amine
reactive N-hydroxysuccinimide (NHS) ester of a (benz) indolium-derived far red fluorescent probe. We show that VT680 diffuses
into leukocytes within minutes, covalently binds to cellular components, remains internalized for days in vitro and in vivo, and
does not transfer fluorescence to adjacent cells. It is biocompatible, keeps cells fully functional, and fluoresces at high
intensities. In a tumor model of cytotoxic T lymphocyte (CTL) immunotherapy, we track and quantify VT680-labeled cells
longitudinally at the whole-body level with fluorescence-mediated molecular tomography (FMT), within tissues at single cell
resolutions by multiphoton and confocal intravital microscopy, and ex vivo by flow cytometry. Thus, this approach is suitable
to monitor cells at multiple resolutions in real time in their native environments by NIR-based fluorescence imaging.
Citation: Swirski FK, Berger CR, Figueiredo J-L, Mempel TR, von Andrian UH, et al (2007) A Near-Infrared Cell Tracker Reagent for Multiscopic In Vivo
Imaging and Quantification of Leukocyte Immune Responses. PLoS ONE 2(10): e1075. doi:10.1371/journal.pone.0001075
INTRODUCTION
The growing appreciation that cellular and molecular mechanisms
are controlled by the microenvironment in which they operate–in
vitro models seldom recapitulate in vivo behavior–indicates a need
to simultaneously monitor biological processes at various scales
non-invasively. Optical imaging now allows in vivo visualization of
biology as it unfolds, with relatively little perturbation of the native
environment, but multi-scopic imaging that integrates single-cell
and whole-body information from the same animal is often not
possible, partly because of inadequate reporter tags. Most
fluorescent cell tracker dyes emit at wavelengths under 650 nm
(CFSE, CMTPX, BODIPY 630, DDAO-SE), where light is
efficiently absorbed and scattered, thus limiting meso/macro-scopic
analysis. Moreover, tissue autofluorescence at visible wavelengths
confounds discrimination between target and background signal and
is much lower in the NIR [1]. While design of cell trackers in the far
and near-infrared region of the light spectrum partly resolves these
problems, cell trackers must also be considered for multiphoton
excitation, biocompatibility, and cellular retention if they are to
report effectively on biology. Their optimization, therefore, remains
a challenge for multi-scopic imaging.
Optical methods in current use include epifluorescence, confocal
and multiphoton (MP) intravital microscopy (IVM) and fluorescence-
mediated molecular tomography (FMT). For analysis at the
mesoscopic level, FMT permits longitudinal assessment of fluoro-
chrome concentrations in the whole body of mouse models [2].
Measurements are inherently quantitative and three-dimensional and
the method has been used to report on enzyme activity, in-
flammation, and phagocytosis [1,2]. At the microscopic level, IVM
permits the dynamic study in situ of cell migration and cell-cell
interactions in living animals in three dimensions [3–5]. Recent
studies have used MP-IVM to explore the migratory and interactive
activities of immune cells with their environment [3,6–11]. Harnes-
sing the capacity of these technologies to provide insight, in a single
mouse with one reporter, into how cell-cell interactions influence and
are influenced by their larger environment, is an unmet need.
In this study, we evaluated whether VT680 (peak excitation
67065 nm, peak emission 68865 nm), a near-infrared fluoro-
chrome NHS ester, can be used as a multi-scopic cell tracker for in
vivo optical imaging; we compared it to CFSE, a cell tracker
currently available and in wide use at the microscopic level. We
tested the capacity of VT680 to label and remain in cells, to keep
cells alive and functional, and to report on biodistribution and T
cell behavior in a tumor model of adoptive transfer immunother-
apy in vivo using FMT and IVM, and ex vivo by flow cytometry.
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VT680 efficiently labels cells, remains internalized in
vitro and in vivo, and does not interfere with cell
function
To test the cell-labeling capacity of VT680 we used readily
abundant mouse splenocytes as a first model. Freshly isolated
splenocytes were incubated for 30 min at 37uC with increasing
doses of the fluorochrome. Mean fluorescent intensity (MFI), as
determined by flow cytometry (FCM) (Laser Ex: 635; Em filters:
685/LP, 695/40), showed that VT680 tagged cells efficiently;
increasing doses corresponded to increasing MFI and reached
4610
4 with 300 mg/mL compared to ,10 MFI for control
unlabeled cells (Fig. 1A). Concurrent analysis of cell survival
immediately after labeling showed that VT680 was not toxic at
doses up to 30 mg/mL (Fig. 1B). For all subsequent experiments,
cells were labeled with 30 mg/mL, thus ensuring high MFI
(1610
4–1.3610
4) and high viability (.95%). To assess fluoro-
chrome retention, we investigated kinetics of VT680 release from
resting (Fig. 1C) or dividing cells (Fig. 1D), daily for three days
after labeling. In parallel, cells were stained with CFSE (5 mM),
a gold standard tracer for ex vivo cell tracking [12]. When
compared to MFI obtained immediately after labeling, VT680
fluorescence of resting cells was close to 100% during three days of
culture (Fig. 1C). In contrast, 1 log of fluorescence was lost within
the first 24 h when cells were labeled with CFSE, and continued to
decrease for the next two days at a slower rate, albeit at a rate
slightly higher compared to VT680 (20.19 log/day for CFSE vs
20.06 log/day for VT680). The large loss of CFSE shortly after
labeling may reflect CFSE staining a compartment that is rapidly
exchanged, and the loss may indeed occur at times earlier than
24 h. VT680 retention, therefore, was at least as good as, if not
better than, CFSE. Labeling did not alter survival of the cultured
cells (data not shown). Similarly, in dividing cells, fluorescence loss
was higher for CFSE than for VT680 (Fig. 1D). However,
fluorescence in dividing cells was not characterized by discrete
peaks as observed for CFSE, but rather a streak. It is possible this is
a function of detecting fluorescence in the far-red range. Of note,
injection of VT680 in vivo efficiently labeled circulating and
splenic leukocytes but this untargeted agent was not selective for
any cell type (data not shown).
To further determine the cellular distribution of VT680, labeled
cells were fixed and stained with CFSE and propidium iodide (PI).
As expected, CFSE, which binds amine groups, labeled the
cytoplasm abundantly, while PI targeted the nucleus. Confocal
microscopy analysis showed heterogeneous labeling by VT680 in
the cell membrane, cytoplasm, and nucleus (Fig 1E). This
heterogeneous labeling may also explain why discrete peaks were
not observed for proliferating cells; subsequent cell division would
not lead to equal distribution of the dye among daughter cells.
Quantification of the relative distribution of VT680 involved a bio-
cellular assay in which cellular compartments were extracted and
analyzed separately. By this method, VT680 was shown to
accumulate in the cell membrane, cytoplasm, and nucleus of both
resting and dividing cells (Fig 1F). VT680 uptake by dividing T
cells compared to resting cells was higher in the cytoplasm (80% vs
35%), but lower in the cell membrane (8% vs 25%) and nucleus
(12% vs 40%), likely because the cytoplasm of cells selectively
increases in size upon activation.
To investigate whether labeled cells can transfer VT680 to
unlabeled neighboring cells, we co-cultured VT680-labeled
Thy1.1 T cells with unlabeled Thy1.2 T cells (Fig 1G). All
Thy1.1 T cells fluoresced at the wavelength indicative of VT680
while none of the Thy1.2 T cells showed VT680 fluorescence
above background, demonstrating that VT680 did not transfer to
adjacent cells. Moreover, VT680-labeled T cells retained their
capacity to produce cytokines upon stimulation with PMA and
Ionomycin, as evidenced by similar IFN-c secretion (Fig. 1H).
We next analyzed the capacity of VT680-labeled cells to retain
the fluorochrome in vivo. Thy1.2 splenocytes labeled ex vivo with
either VT680 or CFSE were injected i.v. into Thy1.1 mice. Mice
were euthanized at days 0 (i.e. ,10 minutes), 1 and 3 d after
injection, spleen was harvested, and donor cells were identified
with anti-Thy1.2 antibody. Mean fluorescent intensity after 3 days
neared ,100% of the original label, while the MFI of CFSE-
labeled cells decreased to 10% (Fig. 1I), a finding in line with our
previous in vitro observations (Fig. 1C). In parallel, to test whether
VT680 activates cells in vivo, we measured levels of CD25 and
CD44 expression on Thy1.2 (VT680
+) and Thy1.1 (unstained)
cells (Fig. 1J). We found similar expression of both receptors at all
time points, suggesting that VT680 does not induce T cell
activation in vivo.
VT680-labeled cytotoxic T lymphocytes (CTLs)
remain functional and can be tracked individually in
vivo
The ability of VT680 to prominently and stably label cells in vitro
and in vivo suggests that the fluorochrome may be used as
a reporter for cell migration and function in disease models. To
test this, we employed a well-characterized tumor model of
adoptive transfer immunotherapy. Tumors expressing a model
Hemagglutinin (HA)-antigen were implanted s.c. in the hind paw
and their growth was monitored for the duration of the experiment
(Fig. 2A). In parallel, we expanded HA–specific CTLs in vitro. We
obtained these cells from TCR-CL4 RAG
2/2 Thy1.2 BALB/c
mice that express a transgenic TCR specific for the Kd–restricted
HA512-520 peptide. When stimulated in vitro with cognate peptide
and IL-2, HA-specific CTLs kill HA
+ CT44 tumor cells efficiently
and selectively [13,14]. Seven days after tumor implantation,
Thy1.2
+, HA-specific CD8
+ cytotoxic T lymphocytes (CTLs) were
tagged in vitro with VT680 and injected i.v. into Thy1.1
+ tumor-
bearing mice. Unlabeled CTLs served as controls. VT680-labeled
CTLs were as efficient at controlling tumor growth as unlabeled
CTLs (Fig. 2A), demonstrating that the imaging agent did not alter
the CTL response in vivo. Five days after CTL injection, mice
were euthanized and donor Thy1.2
+ cells retrieved from the
tumor-draining lymph nodes (Fig. 2B) and tumor (Fig. 2C).
Retrieved numbers of Thy1.2
+ CTLs were similar irrespective of
VT680 labeling. Consistent with in vitro observations (Fig. 1D &
G), Thy1.2
+ CTLs labeled with VT680 remained fluorescent, did
not transfer fluorescence to adjacent cells, and showed the same
level of CD25 and CD44 expression when compared to unlabeled
CTLs, further substantiating the conclusion that VT680 does not
alter cell function.
We next tested whether immune cells labeled with VT680 can
be detected by intravital microscopy. To this end, we injected 10
7
VT680-labeled HA-specific CTLs i.v. into mice with GFP+ HA-
expressing CT44 tumors growing in skin-fold chambers. We found
that both confocal (excitation: 637 nm, emission: 660/LP) and
multiphoton (excitation: 820 nm, emission: 560/LP, 620/100 nm
BP) microscopy allowed detection of the CTL in tumor-associated
stroma. Around two days after adoptive transfer, CTLs accumu-
lated at the periphery of the bulk of tumor cells, (Fig 2D and
Movie S1) while only few CTLs were found inside the tumor
(Fig 2E). Around four days after adoptive transfer, more CTLs had
accumulated inside the tumors (Fig 2F). In line with two recent
reports [15,16], CTLs in stroma of regressing tumors initially
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PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1075Figure 1. VT680 efficiently labels splenocytes, remains internalized in vitro and in vivo, and does not interfere with cell function. A. Splenocytes
were incubated with increasing doses of VT680 and mean fluorescent intensity (MFI) for each dose is shown. B. Viability of splenocytes after labeling
with increasing doses of VT680. C. In vitro retention of VT680 and CFSE in resting cells for three days after labeling (log scale). D. In vitro retention of
VT680 and CFSE in dividing cells for three days after labeling (log scale). E. Cellular distribution of VT680 assessed microscopically. F. Cellular
distribution of VT680 in resting and dividing cells assessed with a bio-cellular assay. G. VT680-labeled Thy1.1 cells were mixed in a 1:1 ratio with
unlabeled Thy1.2 cells and cultured together. A different group was cultured separately. 24 h later VT680 retention was assessed in Thy1.1
+ (Gate i)
and Thy1.2
+ (Gate ii) cells. H. Expression of IFN-c on naı ¨ve cells (thick-line histogram) and cells stimulated with PMA/Ionomycin (shaded histogram)
that were either unlabeled or labeled with VT680. I. Retention of VT680 in vivo. Thy1.2 splenocytes were labeled with VT680 or CFSE ex vivo and
injected to Thy1.1 mice. At indicated times recipient spleens (Thy1.1) were harvested and retention of label on donor cells (Thy1.2) was calculated. J.
CD25 and CD44 expression. Thy1.2 splenocytes were labeled with VT680 and injected to Thy1.1 mice. At indicated times recipient spleens were
harvested and CD25 and CD44 expression was measured on VT680-labeled, Thy1.2 donor splenocytes and unlabeled, Thy1.1 cells of recipient mice.
Mean and SEM are shown, n=3–5.
doi:10.1371/journal.pone.0001075.g001
Imaging of Immune Responses
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1075interacted for prolonged periods of time with tumors and thus
displayed relatively low velocity/motility. Disappearance of tumor
cells at later time points coincided with the detection of CTL that
now showed higher velocity/motility and that did not interact with
tumor cells, at least during the 30–60 min recordings (Fig 2 E & F).
Of note, we observed that tumor cells could be simultaneously
attacked by two CTLs (see Fig 2F, cells #1 & 2 and Movie S2),
which is in contrast with our previous observations in which CTL
attack of antigen-pulsed B cells was always characterized by
monogamous interactions [10]. Here we show that VT680 can be
Figure 2. VT680-labeled cytotoxic T lymphocytes (CTLs) remain functional and can be tracked individually in vivo. CT44 tumors were injected s.c.
into hind paws of Thy1.1 mice. After 7 days, activated Thy1.2 HA-specific CTLs either labeled with VT680 or unlabeled were injected i.v. A. Tumor
growth kinetics in mice that did not receive CTLs and in mice that received VT680 and unlabeled CTLs. B. Relative distribution and activation status of
VT680-labeled and unlabeled donor Thy1.2 CTLs retrieved from the tumor-draining lymph nodes. C. Relative distribution and activation status of
VT680-labeled and unlabeled donor Thy1.2 CTLs retrieved from the tumor. Mean and SEM are shown, n=3. D. Overview of tumor bulk. E.
Multiphoton microscopy on day 2 after adoptive transfer. Paths of cell migration are shown in the last panel. F. Intravital microscopy on day 4. T cells
(red) are in close contact to a cancer cell (green), which shows phenotypic changes suggestive of ongoing apoptosis. Paths of cell migration are
shown in the last panel.
doi:10.1371/journal.pone.0001075.g002
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experiments in combination with other markers for multicolor
imaging to simultaneously track multiple cell types. The dye
became highly compartmentalized in T cells, appearing as bright
puncta in the uropod of migrating cells. Moreover, we found that
VT680-labeled CTLs could be detected for up to 6 days after
injection, thus allowing the investigator to study the unfolding of
immune responses over rather large periods of time.
VT680-labeled CTL biodistribution can be quantified
and tracked non-invasively in vivo
Microscopy studies with VT680-labeled tumor-reactive CTLs
permit visualization of efficient killing at the single-cell level, but
are insufficient at determining the biodistribution and number of
tumor reactive CTLs accumulating at the stroma. Complementing
these studies with a quantitative mesoscopic modality such as
fluorescent-mediated molecular tomography (FMT) would provide
further insight into the specificity, scope, and magnitude of the
response. As VT680 emits at a NIR wavelength where auto-
fluorescence and tissue absorbance are minimal, we hypothesized
that the agent’s optical properties will allow concurrent mesoscopic
evaluation of CTL activity. HA-bearing tumors were implanted
and allowed to grow. Six days later, VT680-labeled HA-specific
CTLs were injected. Mice were imaged before CTL injection and
on three consecutive days after injection. Regions of interest (ROI)
were generated around the tumor and the draining lymph node as
well as on the corresponding locations on the contralateral leg.
VT680 signal was elevated in HA-bearing tumors for the duration
of the experiment (Fig 3A). Fluorescence appeared within the
tumor one day after CTL transfer and remained high for several
days throughout the tumor bulk, as assessed by slices through the
Z plane (Fig. 3B and Movie S3). Correspondingly, fluorescence in
the tumor-draining lymph nodes was higher in legs implanted with
tumors compared to the contra-lateral leg. In contrast, low
fluorescence was observed in the contra-lateral leg and the
corresponding lymph node, indicating migration of some HA-
specific CTLs at sites not expressing HA. This was consistent with
flow cytometric analysis (data not shown).
To establish whether FMT, a modality with the advantage of
being inherently quantitative, can be used to predict the number of
cells at the tumor site, several parameters were considered. First,
fluorescence signal, quantified in nM fluorescence units (Fig 3C),
showed more pronounced fluorescence in tumor-bearing paws and
tumor-draining lymph nodes. So as to determine the relationship
between nM and number of cells, phantom experiments were
conducted with known cell number implanted s.c. (Fig 3D).
Average number of cell divisions, as occurs in vivo, could be
calculated because VT680 does not lose fluorescence in resting
cells (Fig 1C & D and Fig 3E). By taking these variables into
account, it was determined that ,7610
4 CTLs were present at the
tumor 3 days after injection and ,4610
4 CTLs could be found in
the draining lymph nodes. This was consistent with the number of
cells retrieved from lymph nodes and determined with the use of
flow cytometry (4–10610
4). Together, these data show that
biodistribution can be quantified non-invasively in vivo over time
and that CTLs continue to accumulate in the tumors and lymph
nodes during the course of the experiment.
DISCUSSION
In this study, we show that VT680, a near-infrared fluorochrome
NHS ester, allows tracking of cells with multiple in vivo imaging
modalities at different scales. FMT monitors distribution of cells in
the entire animal while IVM and MP-IVM allow for zooming into
specific regions of interest for analysis of activity at the single cell
level. The agent diffuses into cells within minutes, internalizes in
various cellular compartments, is fully biocompatible, remains
internalized for days in vitro and in vivo, and does not transfer
fluorescence to adjacent cells. In comparison, cells labeled with
widely used dyes such as CFSE lose on average one order of
magnitude of fluorescence within 24 hours.
Cells in their native environment can behave differently
compared to cells that are placed in culture [10]. In vivo, cell
behavior is influenced by multiple other factors such as complex
anatomical features, forces of fluid flow, the extracellular matrix,
as well as adhesion with neighboring cells and mixtures of
cytokines. Understanding the activity and function of immune cells
Figure 3. VT680-labeled CTL accumulation can be quantified and tracked mesoscopically in vivo. CT44 tumor cells were injected s.c. in the right
hind paws. After 7 days of growth VT680-labeled HA-specific CTLs were injected. A. Fluorescent-mediated molecular tomography (FMT) depicting
kinetics of CTL accumulation in tumor and lymph nodes. B. Z stacks of FMT images on day 8. C. Correlation of FMT signal vs days after CTL transfer in
tumors (white) and draining lymph nodes (black) from the right, tumor-bearing, paw (circles) and the left, contra-lateral, paw (triangles). D. Number of
cells vs. fluorescence determined by phantom experiments. E. Average number of CTL cell divisions during 5 d after injection determined by VT680
fluorescence loss. F. Estimation of CTL accumulation in tumors (white) and draining lymph nodes (black) from the right, tumor-bearing, paw (circles)
and the left, contra-lateral, paw (triangles), determined by combining information from D and E.
doi:10.1371/journal.pone.0001075.g003
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necessitates development of in vivo imaging technologies that are
robust and quantitative. Cell labeling agents already available for
optical imaging such as GFP, RFP, CFSE, and CMTMR are
useful for microscopic applications but are less suitable for
mesoscopic analysis as they offer limited tissue penetration.
VT680 penetrates tissue because hemoglobin, water, and lipids
have their lowest absorption coefficients in the NIR region of 650–
900 nm. As a result, VT680 may be used not only for ex vivo flow
cytometric analysis but also for several in vivo imaging modalities
that track accumulation both mesoscopically and microscopically.
The combination of micro and mesoscopic imaging in the same
animal offers several advantages because it allows the simultaneous
evaluation of cellular activity and biodistribution. Such advances
will foster a systems approach in which activities at the cell level
are evaluated in the context of the entire animal.
MATERIALS AND METHODS
Animals
Female Balb/c (Thy1.2
+) mice were purchased from Taconic
farms (Germantown, NY, USA). TCR-CL4 RAG
2/2 BALB/c
mice expressing a TCR specific for K
d/HA512-520 were generated
as described [13]. DUC18 BALB/c mice expressing a TCR
specific for K
d/tERK-I 136-144 [17] and Thy1.1 BALB/c mice
were obtained from Dr. Paul Allen and bred in-house. All animals
were housed in a specific pathogen-free environment and used at 8
to 15 weeks of age. The institutional subcommittee on research
animal care approved all animal studies.
Cells
Single cell suspensions were prepared by homogenizing the spleen
(Potter
TM homogenizer) and filtering single-cell suspensions through
70 mm cell strainers. Cells were washed twice and resuspended in
complete medium for further experiments. The following complete
medium was used: 86% vol. RPMI 1640, 1 mM sodium pyruvate,
10 mM HEPES, 2 mM glutamine, 1% penicillin/streptomycin,
50 mM mercaptoethanol, 10% FCS. To stimulate splenocyte
proliferation, 4610
6 cells were cultured in 1 ml complete medium
for 3 days supplemented with purified anti-CD28, 37.51 (2 mg/ml,
BD BioSciences) and recombinant (r)IL-2 (20 ng/ml, R&D Systems)
in 24-well plates that had been previously coated for 1 h at 37uC
withpurifiedanti-CD3,145-2C11(1.5 mg/well,BDBiosciences).To
stimulate CL4 cell proliferation, cells were cultured in complete
medium with 1 mg/mL HA512-520 p e p t i d ef o r1h ,w a s h e da n d
maintained at 37uC. Starting on day 2 and every second day, cells
were harvested and incubated in fresh complete medium supple-
mented with 20 ng/ml rhIL-2 (R&D Systems) until day 7.
Cell labeling
VivoTag 680 (VT680; Ex: 67065 nm, Em: 68865 nm; MW:
1240 gmol
21) was commercially obtained from VisEn Medical
(Woburn, MA), dissolved in DMSO and stored in aliquots of
10 mg/ml at 220uC. Sufficient volume to ensure a final VT680
concentration of 0.3, 3, 30 or 300 mg/ml was added to
4610
6 cells/ml previously resuspended in complete medium at
37uC. A dose of 30 mg/ml corresponds to 24.1 mM. Cells were
incubated with VT680 at 37uC for 30 min at 5% CO2. The cells
were washed twice after labeling. Preliminary experiments showed
that presence of serum does not impair cell labeling. Cells were
incubated in the presence of different doses of VT680 for 30 min
at 37uC. For CFSE labeling, cells were incubated in 5 mM CFSE
in RPMI for 15 minutes at 37uC. Cell viability was assessed
microscopically with Trypan Blue exclusion (Cellgro Mediatech,
Inc.) and further corroborated with the forward scatter vs. side
scatter profile. For intracellular dye localization, cells were first
labeled with VT680, fixed with Cytofix/Cytoperm
TM kit (BD
Biosciences, USA), then labeled with PI (propidium iodide) (1/
1000) to identify the nucleus. Cells were prepared on slides by
cytocentrifugation (Shandon, Inc.) at 106g for 2 min (Shandon,
USA). Ex vivo cell observations were made on a Zeiss Axiovert
200 microscope with fluorescence and bright-field capabilities. For
cell fractioning, the subcellular proteome extraction kit (ProteoEx-
tractH, CalbioChem, USA) was used according to the manufac-
turer’s protocol. Briefly, VT680 labeled splenocytes were succes-
sively sedimented three times. Owing to different extraction
buffers, we collected four different fractions containing the cytosol,
the membrane protein extract, proteins from the nucleus, and
proteins of the cytoskeletal matrix. VT680 was quantified by
measuring the near infrared fluorescence (Excitation: 670615;
Emission: 700615) of each fraction in a photometer microplate
reader (safire2, TECAN, Durham NC, USA). Amount of VT680
in each fraction was referenced to a standard curve (increasing
concentration of VT680 diluted in PBS).
Flow cytometry
Cells were incubated with the following mAbs: Thy1.2 (CD90.2)-
PE, 53-2.1; Thy1.1 (CD90.1)-FITC, OX-7; IFN-c- FITC,
XMG1.2; CD25-FITC, clone; CD44-APC, IM7; CD8-PerCP,
53-6.7. For intracellular staining of IFN-c cells were stimulated for
5 h with 1 mg/ml phorbol 12-myristate 13-acetate (PMA) and
0.25 mg/ml Ionomycin and in the presence of 10 mg/ml Brefeldin
A after 1 h (Sigma-Aldrich) and permeabilized and fixed with
a Cytofix/Cytoperm Kit (BD Biosciences). Data were acquired on
an LSRII (BD Biosciences). To detect VT680, a red Helium-Neon
635 nm laser was used for excitation and a 685/LP and 695/40
filter configuration was used for detection.
Adoptive transfer and tumor model
The tumor cell line CT44 was generated by transfecting CT26
cells (a cell line derived from a chemically induced murine colon
carcinoma) with a fusion protein of influenza hemagglutinin and
EGFP [13]. Anesthetized animals received 10
6 tumor cells in
50 mL PBS s.c. into the upper side of the hind paw. 10
7 VT680 or
CFSE-labeled Thy1.2 splenocytes were injected intravenously.
Tumor size was monitored on a daily basis using a caliper.
Confocal and multiphoton microscopy
In vivo monitoring of cell migration was performed in the dorsal
skin fold chamber model, as previously described [18]. On day
zero, 10
6 tumor cells were injected i.m. in the center of the
window. After 6 days, VT680-labeled CL4 cells were injected i.v.
Confocal and multiphoton microscopy experiments were per-
formed on days 7 to 10. For laser scanning microscopy (Olympus
IV100), VT680 was excited with a red laser diode of 637 nm and
detected with a 660/LP filter. For multiphoton microscopy (on
a BioRad Radiance 2100 MP centered around an Olympus BX51
equipped with a 206/0.95 NA objective lens), the dye was excited
with a pulsed Ti:Sapphire laser (MaiTai HP, Spectra-Physics)
tuned to 820 nm. This wavelength was chosen because VT680 has
a peak in its two-photon cross-section at 820 nm. Since our
available detection optics were suboptimal for collection of VT680
emission, which is maximal at 688 nm, we prioritized optimal
excitation of VT680 over that of eGFP, for which we otherwise
found 920 nm to be optimal. Although excitation of eGFP is
suboptimal at 820 nm, visualization of tumor cells was still possible
due to their high expression of eGFP. A 560 nm DCLP filter and
Imaging of Immune Responses
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detection of VT680, while EGFP emission and second harmonic
signals from collagen were recorded using 515/30 nm and 400/
40 nm bandbass filters, respectively. For four-dimensional record-
ings of T cell migration in tumors, stacks of 11 optical sections
were acquired every 30 seconds for 30 minutes with an optical
zoom of 36 to provide image volumes of 40 mm in depth and
208 mm in width and length. Sequences of image stacks were
transformed into volume-rendered, four-dimensional movies using
Volocity software (Improvision, Coventry, UK) and exported as
Quicktime movies. Motion-artifacts in recordings were corrected
using the auto-alignment plugin (stackreg) of ImageJ (http://rsb.
info.nih.gov/ij/).
FMT
Three to five days prior to imaging mice were placed on a low
manganese diet (Harlan, Indianapolis IN) to reduce autofluores-
cence caused by normal mouse chow when imaging. The imaging
site (hind paws and legs up to the knee joint) was shaved and
depilated to remove all hair, which is a source of interference with
fluorescent imaging. Mice were imaged on the FMT system
(VisEn Medical) before injection and on days 1–4 following i.v.
injection of labeled cells. Mice were anesthetized by inhalation of
isoflurane, and placed on the imaging cartridge. Anesthesia was
maintained by the use of a nose cone, and mice were placed within
the imaging chamber. Reflectance images were taken in white
light and fluorescent modes. The imaging chamber was filled with
an index matching solution (VisEn Medical) as per the vendors
instructions. Non-invasive fluorescent tomographic imaging was
carried out in the VT680 channel. After imaging, the chamber
was drained, the mouse removed, and allowed to recover. The
FMT software allows for the 3D reconstructions of the imaging
data utilizing a normalized Born equation. Following the
reconstruction, volumes of interest (VOI’s) were selected by
drawing regions of interest (ROI’s) in all 3 imaging planes (X, Y,
Z). A mean fluorescent value and total VOI volume and
fluorochrome concentration were generated for VOI’s encom-
passing the hind paws and the draining lymph nodes. FMT
phantom experiments were performed to generate standard curves
and calibrate the FMT system for the VT680 fluorochrome.
Phantoms consisted of pure VT680 dye diluted into PBS at various
concentrations and VT680-labeled cell suspensions in PBS.
SUPPORTING INFORMATION
Movie S1 Multiphoton intravital microscopy of tumor bulk on
day 2 after T cell transfer. Tumor cells (green) are in contact with
VT680-labeled T cells (red). Collagen fibers (blue) are seen.
Found at: doi:10.1371/journal.pone.0001075.s001 (0.49 MB
MOV)
Movie S2 Confocal intravital microscopy of the tumor bulk on
day 4 after T cell transfer. VT680-labeled T cells (red) engage
a cancer cell (green).
Found at: doi:10.1371/journal.pone.0001075.s002 (0.52 MB
MOV)
Movie S3 Fluorescence-mediated molecular tomography on day
1 after VT680-labeled T cell transfer. Fluorescence is seen through
Z stacks at the tumor and the tumor draining lymph node.
Found at: doi:10.1371/journal.pone.0001075.s003 (0.03 MB
MOV)
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